Stock Events

Stock Events

Search...

Virios Therapeutics

$0.16

47

-$3.29-95.5% Tuesday 20:00

Statistics

Day High

0.21

Day Low

0.14

52W High

26

52W Low

0.14

Volume

42,356,733

Avg. Volume

87,787

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

13MarExpected

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Q3 2024

Q4 2024

-2.05

-1.37

-0.68

0

Expected EPS

-1.36

Actual EPS

N/A

Financials

-Profit Margin

Unprofitable

2018

2019

2020

2021

2022

2023

0Revenue

-6.4MNet Income

Analyst Ratings

$12.00Average Price Target

The highest estimate is 12.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VIRI. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Gilead Sciences

Gilead Sciences focuses on antiviral drugs, directly competing with Virios in the antiviral space.

Merck & Co. develops treatments for infectious diseases, including antivirals, making it a direct competitor.

GlaxoSmithKline has a strong portfolio in antiviral drugs, competing in the same market as Virios.

AbbVie has a significant presence in the antiviral drug market, making it a competitor to Virios.

Pfizer develops and markets antiviral medications, positioning it as a competitor to Virios.

Bristol-Myers Squibb

Bristol Myers Squibb offers antiviral drugs, competing with Virios in the pharmaceutical market.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical division, competes in the antiviral space with Virios.

Vertex Pharmaceuticals

Vertex Pharmaceuticals is involved in the development of antiviral treatments, making it a competitor.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals focuses on infectious diseases, including antivirals, competing with Virios.

Novartis AG has a diverse portfolio that includes antiviral drugs, competing with Virios in the pharmaceutical market.

About

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

Show more...

CEO

Employees

4

Country

US

ISIN

US92829J1043

Listings

0 Comments

Share your thoughts

FAQ

What is Virios Therapeutics stock price today?▼

The current price of VIRI is $0.16 USD — it has decreased by -95.5% in the past 24 hours. Watch Virios Therapeutics stock price performance more closely on the chart.

What is Virios Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Virios Therapeutics stocks are traded under the ticker VIRI.

What is Virios Therapeutics revenue for the last year?▼

Virios Therapeutics revenue for the last year amounts to 0 USD.

What is Virios Therapeutics net income for the last year?▼

VIRI net income for the last year is -6.4M USD.

How many employees does Virios Therapeutics have?▼

As of April 05, 2026, the company has 4 employees.

In which sector is Virios Therapeutics located?▼

Virios Therapeutics operates in the Professional, Scientific, and Technical Services sector.

When did Virios Therapeutics complete a stock split?▼

Virios Therapeutics has not had any recent stock splits.